Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients

Depletion of Serotonin and Selective Inhibition of 2B Receptor Suppressed Tumor Angiogenesis by Inhibiting Endothelial Nitric Oxide Synthase and Extracellular Signal-Regulated Kinase 1/2 Phosphorylation

(2015) Masanori Asada et al.   NEOPLASIA

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

(2012) Else Maae et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours

(2012) U Lassen et al.   BRITISH JOURNAL OF CANCER

Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model

(2012) Femke Heindryckx et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma

(2012) Shih-Jung Cheng et al.   ORAL ONCOLOGY

Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases

(2011) Nuh N. Rahbari et al.   ANNALS OF SURGICAL ONCOLOGY

Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

(2011) F Fan et al.   BRITISH JOURNAL OF CANCER

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia

(2011) Thomas Schmidt et al.   CANCER CELL

Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept

(2011) J. F. de Groot et al.   CLINICAL CANCER RESEARCH

Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects

(2011) Titti Martinsson-Niskanen et al.   CLINICAL THERAPEUTICS

Preoperative Serum Placenta Growth Factor Level Is a Prognostic Biomarker in Colorectal Cancer

(2011) Shu-Chen Wei et al.   DISEASES OF THE COLON & RECTUM

Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression

(2011) Francesco Panzuto et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy

(2011) J. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement

(2010) A P Taylor et al.   BRITISH JOURNAL OF CANCER

Anti-Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation

(2010) L. Coenegrachts et al.   CANCER RESEARCH

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

(2010) Sara Van de Veire et al.   CELL

Chromogranin A and the Tumor Microenvironment

(2010) Angelo Corti   CELLULAR AND MOLECULAR NEUROBIOLOGY

Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia

(2010) J. Schiettecatte et al.   CLINICAL BIOCHEMISTRY

Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors

(2010) K. M. Detjen et al.   CLINICAL CANCER RESEARCH

Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer

(2010) Michael B. Bass et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Neuropilins in Tumor Biology

(2009) A. Bagri et al.   CLINICAL CANCER RESEARCH

Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis

(2009) R Srirajaskanthan et al.   ENDOCRINE-RELATED CANCER

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

(2008) U.-F. Pape et al.   ENDOCRINE-RELATED CANCER

Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy

(2008) Tomohiro Nakamura et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastroenteropancreatic neuroendocrine tumours

(2008) Irvin M Modlin et al.   LANCET ONCOLOGY